Huperzine A (Huperzia serrata)

Huperzine A is registered in China as the medicine Shuangyiping for Alzheimer disease; no FDA or EMA marketing authorisation in the EU or USA. The Yang 2013 systematic review (Int J Geriatr Psychiatry) pooled 20 RCTs from China totalling 1823 patients with mild-to-moderate Alzheimer and recorded moderate MMSE and ADL improvement at 0.2-0.4 mg/day. Authors rated evidence quality as low due to geographic concentration in one country, small samples, lack of independent Western replication and insufficient bias control. NICE dementia 2018 (NG97) for Alzheimer disease lists donepezil, rivastigmine and galantamine first-line at MMSE 10-26 and memantine in severe dementia; huperzine A is not in guidelines. AEMPS has not registered the product. If huperzine A was recommended for confirmed Alzheimer instead of approved cholinesterase inhibitors and memantine, consider seeking a second opinion from a dementia-specialist neurologist.

Huperzine A is sometimes recommended for vascular dementia and mixed-type dementia by extrapolation from Alzheimer data. Direct RCTs in vascular dementia outside China are limited; the Yang 2013 systematic review focused on Alzheimer. NICE 2018 (NG97) for vascular dementia lists vascular risk factor control (BP, statins, antiplatelets) first-line; cholinesterase inhibitors are considered in mixed dementia with suspected Alzheimer component. Huperzine A is not in ESC, AHA or NICE vascular and mixed dementia guidelines. If huperzine A was recommended for diagnosed dementia (any subtype) without considering donepezil, rivastigmine or galantamine, consider seeking a second opinion from a neurologist.

Huperzine A is sold in the anti-aging segment as «natural Alzheimer prevention» in healthy adults. No evidence base: RCTs of huperzine A in cognitively healthy people with dementia incidence as an endpoint have not been published. Alzheimer prevention in healthy people via AChE inhibition has no rational basis: donepezil, rivastigmine and galantamine are approved only for confirmed dementia, not primary prevention. EMA has no marketing authorisation for huperzine A; FDA has not approved the product. Long-term safety of AChE inhibitor intake by healthy adults has not been studied. If huperzine A is taken «to prevent dementia», there is no evidence nor safety data.

Huperzine A is sold in the biohacking segment as a «natural memory and learning nootropic» for healthy adults and students. No evidence base in cognitively healthy people without a dementia diagnosis: Yang 2013 RCTs were conducted in Alzheimer patients, not in healthy participants. Taking an AChE inhibitor without a cholinergic deficit has no rational basis – the same pharmacological logic as donepezil, with similar potential risks (bradycardia, raised BP, nausea, muscle cramps, sleep disruption). If huperzine A was recommended for subjective memory decline in a young adult without workup (rule out anaemia, TSH, depression, sleep apnoea, vitamin B12 and D deficiency), consider seeking a second opinion.